Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - etoposide phosphate (unii: 528xyj8l1n) (etoposide - unii:6plq3cp4p3) - etoposide 100 mg - etopophos is indicated, in combination with other chemotherapeutic drugs, for treatment of patients with refractory testicular tumors. etopophos is indicated, in combination with cisplatin, for first-line treatment of patients with small cell lung cancer. etopophos is contraindicated in patients with a history of a severe hypersensitivity reaction to etoposide products [see warnings and precautions (5.3)] . risk summary based on animal data and its mechanism of action, etopophos can cause fetal harm when administered to a pregnant woman. etoposide, the active moiety of etoposide phosphate is teratogenic in mice and rats (see data) . advise pregnant women of the potential hazard to a fetus. advise women of childbearing potential to avoid becoming pregnant. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in rats, an intravenous etoposide dose of 0.4 m

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid; sodium acetate - gemcitabine kabi is indicated for, the treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. alone or in combination with cisplatin, for the treatment of patients with bladder cancer. in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. in combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 1138.6 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium acetate; sodium hydroxide; mannitol - gemcitabine kabi is indicated for, the treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. alone or in combination with cisplatin, for the treatment of patients with bladder cancer. in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. in combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 227.72 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium acetate; hydrochloric acid; sodium hydroxide - gemcitabine kabi is indicated for, the treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. alone or in combination with cisplatin, for the treatment of patients with bladder cancer. in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. in combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - etoposide - solution for infusion - 20mg/1ml

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: ethanol; citric acid; polysorbate 80; macrogol 300; benzyl alcohol - small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia; hodgkin's disease non-hodgkin's lymphoma.

Malta - Englisch - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents

Kanada - Englisch - Health Canada

bdh inc. - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents

Kanada - Englisch - Health Canada

pharmel inc - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents

Kanada - Englisch - Health Canada

hospira healthcare ulc - etoposide - solution - 20mg - etoposide 20mg - antineoplastic agents